TL;DR
This study investigated the long-term immune response to COVID-19 vaccines in institutionalized older adults in Argentina, finding that Sputnik V and AZD1222 elicited stronger antibody responses than BBIBP-CorV. While antibody levels waned significantly by 6 months post-vaccination, previous infection and younger age (<80) were associated with higher titers, and the Omicron variant showed reduced neutralization compared to the ancestral strain.
What Problem Does This Paper Address?
The COVID-19 pandemic disproportionately affected older adults, especially those in nursing homes, due to their increased vulnerability to severe illness, hospitalization, and death. Understanding the duration and effectiveness of vaccine-induced immunity in this population is crucial for informing public health strategies, including the need for booster doses and tailored approaches. While initial vaccine efficacy studies often focused on younger, healthier populations, data on the sustained humoral response and neutralizing capacity in elderly, institutionalized individuals across different vaccine platforms was lacking, particularly in the context of emerging SARS-CoV-2 variants.
Methods
The researchers conducted a prospective, multi-centric cohort study involving 851 nursing home residents in Buenos Aires, Argentina. Participants received homologous prime-boost regimens of Sputnik V, BBIBP-CorV, or AZD1222. Plasma samples were collected at multiple time points: baseline, 21 days post-first dose, 21 days post-second dose, and at 120 and 180 days post-first dose.
Key immunological assessments included:
- Anti-Spike IgG levels: Measured using a semi-quantitative ELISA assay to detect specific IgG antibodies against the SARS-CoV-2 Spike protein. Antibody titers were determined as the highest reactive dilution.
- Neutralizing capacity: Assessed using two methods:
- VSV-Spike pseudotyped virus assay: This measured the ability of plasma to inhibit infection by a pseudotyped virus (representing the ancestral B.1 lineage) in VERO cells. The result was expressed as the dilution achieving 50% inhibition (IC50).
- Live SARS-CoV-2 virus assay: This was used to assess neutralization against both the ancestral B.1 lineage and the Omicron variant. Neutralizing titer was defined as the highest plasma dilution showing no cytopathic effect in the cell monolayer.
Statistical analyses involved descriptive statistics, Chi-squared or Fisher's exact tests for categorical variables, and non-parametric tests (Wilcoxon-Mann-Whitney) for comparing groups. Spearman's correlation was used to assess the relationship between IgG titers and neutralizing activity.
Datasets
The study utilized plasma samples collected from 851 nursing home residents in Argentina. These samples were collected longitudinally over a period of 180 days post-vaccination. The study did not introduce new benchmark datasets but rather analyzed data from a real-world cohort.
Key Insights and Ideas
- Vaccine Platform Differences: Sputnik V and AZD1222 demonstrated superior anti-Spike IgG titers compared to BBIBP-CorV in infection-naïve individuals after completing the vaccination schedule. This highlights potential differences in immunogenicity between these platforms in an elderly population.
- Waning Immunity: A significant decrease (3 to 9-fold) in neutralizing capacity was observed across all vaccine platforms by 6 months post-vaccination, underscoring the transient nature of antibody-mediated protection and the potential need for boosters.
- Impact of Prior Infection: Individuals with a history of SARS-CoV-2 infection (convalescent group) generally exhibited higher antibody titers, suggesting that prior exposure can enhance or prolong the immune response to vaccination.
- Age as a Factor: Younger elderly individuals (<80 years) in the infection-naïve group showed significantly higher anti-Spike IgG titers compared to those aged 80 and above. This suggests that age-related immune senescence can impact vaccine response.
- Omicron Escape: Neutralizing capacity against the Omicron variant was substantially lower (10-58 fold) compared to the ancestral B.1 lineage, even after two vaccine doses. This finding emphasizes the challenge posed by emerging variants to vaccine effectiveness.
- Correlation Strength: A strong correlation (rho=0.7 to 0.9) was consistently observed between anti-Spike IgG titers and neutralizing activity, reinforcing the utility of IgG levels as a predictor of functional immunity.
Key Results
- Seroconversion: After two doses, overall IgG seroconversion rates were high: 92.7% for Sputnik V, 68.4% for BBIBP-CorV, and 97.6% for AZD1222 in infection-naïve participants.
- Geometric Mean Titers (GMTs): At 21 days post-second dose, GMTs for Sputnik V and AZD1222 were significantly higher than for BBIBP-CorV. For example, Sputnik V had a GMT of 1374, AZD1222 had 1087, while BBIBP-CorV had only 145.
- Waning: By 6 months post-vaccination, GMTs decreased by 3.7-fold for Sputnik V, 4.4-fold for BBIBP-CorV, and 10.8-fold for AZD1222.
- Neutralization: Neutralizing capacity against Omicron was 10-58 fold lower than against the ancestral B.1 strain at both 21 days post-second dose and 180 days post-first dose.
Limitations and Future Work
- Confounding Factors: The study acknowledges that participants were not assigned to vaccine groups a priori, leading to potential differences in demographics (age, sex) and comorbidities among the groups. While statistical adjustments were made, these imbalances could still influence the results.
- Unreported Infections: A significant portion of the convalescent group (62%) did not report a history of COVID-19 but were seropositive at baseline, highlighting potential underreporting of infections and the challenge of accurately categorizing prior exposure.
- Limited Follow-up: While the study followed participants for 180 days, longer-term follow-up would provide a more complete picture of antibody decay and the need for subsequent doses.
- Future Work: The authors suggest that this data is valuable for informing public health policies, particularly regarding the necessity of booster strategies to enhance protection against emerging variants like Omicron. Further research could explore the impact of heterologous prime-boost strategies and the cellular immune response in this population.
Summary updated